What it's for (Indications)
- Doxazosin, a quinazoline derivative, is clinically indicated for the management of essential hypertension and for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).
- For hypertension, it is used to lower elevated blood pressure, either as monotherapy or in combination with other antihypertensive agents, thereby reducing the risk of cardiovascular events such as stroke and myocardial infarction.
- In BPH, doxazosin acts to alleviate obstructive and irritative urinary symptoms associated with prostatic enlargement, including hesitancy, weak stream, nocturia, incomplete bladder emptying, and urgency, by improving urine flow rates and reducing bladder outflow obstruction.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of doxazosin must be individualized and carefully titrated to achieve the desired therapeutic effect while minimizing adverse reactions. For essential hypertension, the usual initial dose is 1 mg orally once daily. The dose may be gradually increased, based on clinical response and tolerability, at intervals of one to two weeks, to a maximum recommended dose of 16 mg once daily. For the treatment of BPH, therapy typically commences with 1 mg orally once daily. Similar to hypertension, the dose can be titrated upwards based on patient response and tolerance, usually not exceeding 8 mg once daily. Doses should be taken at the same time each day, and an extended-release formulation (e.g., Cardura XL) is also available for once-daily administration, offering sustained drug release. |
Safety & Warnings
Common Side Effects
- Common adverse reactions associated with doxazosin therapy include postural hypotension, dizziness, fatigue, headache, edema (peripheral and facial), somnolence, and rhinitis.
- Patients may also experience nausea, palpitation, and asthenia.
- More significant side effects, though less frequent, include syncope, particularly with the initial dose or during dose escalation (known as the 'first-dose phenomenon'), cardiac arrhythmias, and priapism.
- Patients should be counseled on the potential for these effects, especially dizziness and orthostatic hypotension, which can lead to falls and injury, and advised on mitigation strategies such as rising slowly from a seated or supine position.
- Any persistent or severe adverse effects warrant immediate medical attention.
Serious Warnings
- Black Box Warning: While doxazosin does not carry an FDA-mandated Black Box Warning, clinicians and patients must be acutely aware of the significant risk of severe orthostatic hypotension and syncope, especially upon initiation of therapy or with subsequent dose increases. This potentially serious adverse event, often referred to as the 'first-dose phenomenon,' can manifest as sudden dizziness, lightheadedness, or fainting, potentially leading to falls, injuries, and a substantial impact on patient safety. To mitigate this risk, therapy should always be initiated with the lowest possible dose, administered at bedtime, and patients should be advised to avoid situations where injury could result from syncope for the first several days following initiation or any dose escalation. Concomitant use with phosphodiesterase-5 (PDE5) inhibitors may significantly exacerbate hypotensive effects and should be approached with extreme caution, requiring close monitoring and appropriate dose adjustments.
- Patients initiated on doxazosin, or those undergoing dose escalation, are at significant risk for profound orthostatic hypotension and syncope, a phenomenon commonly referred to as the 'first-dose effect.
- ' This risk is elevated in patients who are volume-depleted, on a sodium-restricted diet, or concomitantly taking other antihypertensive agents, particularly phosphodiesterase-5 (PDE5) inhibitors.
- Close monitoring of blood pressure, especially in the standing position, is crucial.
- Additionally, an association between alpha-1 adrenergic receptor blockers and Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery.
- Patients should inform their ophthalmologist about current or past doxazosin use prior to any ocular surgery to allow for appropriate surgical planning and management to reduce the risk of surgical complications.
- Rare cases of priapism (prolonged, painful erection) have also been reported, requiring urgent medical intervention to prevent permanent erectile dysfunction.
How it Works (Mechanism of Action)
Doxazosin exerts its therapeutic effects through selective antagonism of postsynaptic alpha-1 adrenergic receptors. In the vascular smooth muscle, this blockade leads to a reduction in systemic vascular resistance and a subsequent decrease in both systolic and diastolic blood pressure. This peripheral vasodilation is the primary mechanism by which doxazosin lowers blood pressure in hypertensive patients. In benign prostatic hyperplasia, the blockade of alpha-1 receptors located in the stromal smooth muscle of the prostate, prostatic capsule, and bladder neck leads to relaxation of these muscles, thereby reducing bladder outflow obstruction and improving urinary flow. The selective nature of doxazosin for alpha-1 receptors contributes to its efficacy in both conditions while minimizing some of the generalized adverse effects associated with non-selective alpha-blockers.
Commercial Brands (Alternatives)
No other brands found for this formula.